![]() |
|
|
Vol. 281, Issue 3, 1171-1177, 1997
Departments of Pharmacology (D.B.B., L.J.I., W.J.M.) and Ophthalmology (D.M.C.), University of Nebraska Medical Center, Omaha, Nebraska
| |
Abstract |
|---|
|
|
|---|
The alpha-2 adrenergic receptors are known to be present in the mammalian eye and to mediate the effects of alpha-2 agonists used in the treatment of glaucoma. Little is known, however, regarding the relative densities of the three alpha-2 subtypes in the various tissues of the eye. We used receptor binding experiments with the radioligand [3H]RX821002 to characterize the alpha-2 adrenergic receptors in three tissues of the bovine eye, the ciliary body, retinal pigment epithelium/choriocapillaris and iris. The KD values in the three tissues were similar (0.12-0.14 nM), and the Bmax values ranged from 100 fmol/mg of protein for the ciliary body and retinal pigment epithelium/choriocapillaris to 200 fmol/mg of protein for the iris. The pharmacological characteristics of the alpha-2 receptors in all three tissues of the bovine eye, as assessed by competition studies, were essentially identical and were similar to the characteristics of the alpha-2A/D receptors of the bovine neurosensory retina. The correlation coefficients between the logarithms of the Ki values for the three tissues and the neurosensory retina for nine adrenergic agents were .98 to .99. We conclude that the alpha-2 adrenergic receptors in the ciliary body, iris and retinal pigment epithelium/choriocapillaris of the bovine eye are mainly alpha-2D.
| |
Introduction |
|---|
|
|
|---|
Three major types or subfamilies of
adrenergic receptors have been identified: alpha-1,
alpha-2 and beta. Within each of these three main
types of adrenergic receptors, three or more subtypes have been defined
(Bylund, 1988
, 1992
). Based on pharmacological characteristics and
molecular cloning, the alpha-2 adrenergic receptor subfamily
currently includes three genetic and four pharmacological subtypes:
alpha-2A, alpha-2B, alpha-2C and
alpha-2D (Bylund et al., 1994
). The
alpha-2A adrenergic receptor subtype, for which prazosin and
ARC-239 have relatively low affinity, is found in the human platelet
and the HT29 cell (Bylund et al., 1988
). The gene for this
receptor has been cloned from the human (Kobilka et al.,
1987
), and orthologous clones have been found in the pig (Guyer
et al., 1990
), rat (Lanier et al., 1991
), mouse
(Link et al., 1992
) and guinea pig (Svensson et
al., 1996
). The second subtype, alpha-2B, which has
been identified in neonatal rat lung and the NG108 cell line (Bylund
et al., 1988
), has been cloned from the rat (Zeng et
al., 1990
), human (Lomasney et al., 1990
; Weinshank
et al., 1990
), mouse (Chruscinski et al., 1992
)
and guinea pig (Svensson et al., 1996
) and has a relatively
high affinity for prazosin and ARC-239. A third subtype,
alpha-2C, has been identified in an opossum kidney cell line
(Murphy and Bylund, 1988
), and its cDNA has been identified by
molecular cloning (Blaxall et al., 1994
). Species orthologs
have been cloned from the human (Regan et al., 1988
), rat
(Lanier et al., 1991
), mouse (Link et al., 1992
)
and guinea pig (Svensson et al., 1996
). Although the alpha-2C subtype also has relatively high affinity for
prazosin and ARC-239, its overall pharmacological profile is clearly
different from that of alpha-2B. A fourth pharmacological
subtype, alpha-2D, has been identified in the rat salivary
gland (Michel et al., 1989
) and bovine pineal (Simonneaux
et al., 1991
). This pharmacological subtype has been cloned
from the rat (Lanier et al., 1991
) and mouse (Link et
al., 1992
). On the basis of predicted amino acid sequence, the
alpha-2D appears to be a species ortholog of the human
alpha-2A. Thus, only three subtypes occur in any given
species: alpha-2A/D, alpha-2B and
alpha-2C.
The actions of norepinephrine, an important neuroregulator that
controls many physiological functions in the eye, are mediated by
adrenergic receptors. Numerous agents have been developed that interact
with adrenergic receptors, many of which are used for diagnostic and
therapeutic purposes in ophthalmology. Glaucoma is characterized by a
progressive loss of visual sensitivity resulting from optic nerve
damage. Because high intraocular pressure is the most important risk
factor for glaucoma, the treatment of glaucoma has emphasized the
reduction of intraocular pressure. Adrenergic drugs are effective
ocular hypotensive agents. Currently, beta adrenergic
antagonists are the most commonly used drugs for the medical treatment
of glaucoma (Quigley, 1993
). The alpha-2 adrenergic agonists
are also used for reducing intraocular pressure (Chacko and Camras,
1994
), although their mechanism of action is not clear (Serle, 1994
;
Toris et al., 1995a
, 1995b
). The development of
subtype-selective alpha-2 adrenergic agents for topical
application is considered desirable to reduce both systemic and ocular
side effects. An understanding of the distribution of
alpha-2 receptor subtypes in the eye would be useful in
designing new drugs with greater effectiveness and fewer adverse
effects.
The alpha-2 adrenergic receptors have been identified in
some ocular tissues, including the rabbit iris-ciliary body (Jin et al., 1994
; Mittag and Tormay, 1985
) and the bovine retina
(Bittiger et al., 1980
; Convents et al., 1987
;
Osborne, 1982
; Van Liefde et al., 1993
) by radioligand
binding studies and the rabbit retina by using the inhibition of cyclic
AMP production as the assay (Osborne, 1991
). Autoradiographic studies
have indicated the presence of alpha-2 receptors in rat,
rabbit and human eye (Elena et al., 1989
; Matsuo and
Cynader, 1992
; Zarbin et al., 1986
). This work has clearly
established the presence of alpha-2 receptors in ocular tissues. However, little work has been done on the more important issue
of the identification and localization of the three alpha-2 receptor subtypes in ocular tissues from various species. Antibodies selective for the subtypes have been used in an attempt to localize the
subtypes in the ciliary body of the human and rabbit eye (Huang et al., 1995
). These studies found evidence for all three
subtypes in the rabbit ciliary body but for only alpha-2B
and alpha-2C in the human ciliary body (Huang et
al., 1995
). Previous work from our laboratory using the
radioligand binding assay has established that the bovine neurosensory
retina contains alpha-2A/D but not alpha-2B or
alpha-2C adrenergic receptors (Berlie et al.,
1995
). The presence of the alpha-2D subtype in the bovine
has been recently confirmed by molecular techniques (Venkataraman
et al., 1996
). We present an evaluation of the
characteristics of the alpha-2 adrenergic receptor subtypes
in three additional tissues of the bovine eye: the ciliary body,
RPE/choriocapillaris and iris. On the basis of receptor binding
experiments using the alpha-2 antagonist radioligand
[3H]RX821002, we conclude that the alpha-2
adrenergic receptors in these tissues of the bovine eye are mainly
alpha-2D.
| |
Materials and Methods |
|---|
|
|
|---|
Drugs and chemicals. [3H]RX821002 (specific activity, 55 Ci/mmol) was obtained from Amersham International (London, UK). Rauwolscine, WB 4101 and spiroxatrine were purchased from Research Biochemicals, Inc. (Natick, MA). Oxymetazoline was obtained from Sigma Chemical Co. (St. Louis, MO). The following were gifts: prazosin from Pfizer, Inc. (Groton, CT), ARC-239 from Boehringer-Ingelheim (Ridgefield, CT) and phentolamine from Ciba-Geigy Corp. (Suffern, NY). Prazosin was prepared in methanol, spiroxatrine was prepared in 80% dimethylsulfoxide/20% 1 M HCl, SK&F 104078 was prepared in 50% ethanol and all other drugs were prepared in 5 mM HCl. Drugs were prepared as 5 or 10 mM stock solutions and diluted in 5 mM HCl.
Tissue preparation.
Bovine eyes (Pel-Freez Biologicals,
Rogers, AR) were thawed and cut coronally 7 to 8 mm posterior to the
limbus while bathed in 50 mM Tris buffer at 4°C. The vitreous and
lens were discarded, and the iris was separated from its attachment on
the ciliary body. The remnants of neurosensory retina,
RPE/choriocapillaris, were trimmed from the anterior portion of the
bisected globe, and the ciliary body was dislodged from the scleral
spur. The RPE/choriocapillaris were detached from the posterior pole
after the neurosensory retina was removed. The various tissues were suspended in 25 ml of ice-cold 50 mM Tris·HCl, pH 8, and homogenized with a Polytron (model PT 10-35; Brinkman, Westbury, NY). The homogenate was filtered through a 53-µm nylon mesh and centrifuged at
1,400 rpm for 10 min. The supernatant was transferred to another tube,
recentrifuged at 20,000 rpm for 10 min and frozen at
80°C.
Radioligand binding assays.
Saturation and competition
binding experiments were performed as described previously using 25 mM
sodium phosphate buffer at pH 7.4 (Berlie et al., 1995
;
Bylund et al., 1988
; Deupree et al., 1996
).
Briefly, saturation experiments were performed using two sets of
duplicate tubes that contained 970 µl of membrane suspension and 20 µl of [3H]RX821002 (final concentration, 0.24 ± 0.04 nM). The protein concentration was adjusted to ensure that the
specifically bound radioligand was <10% of the total added
radioligand. One set contained 10 µl of 100 µM (
)-norepinephrine
to determine nonspecific binding. Specific binding was calculated as
the difference between total and nonspecific binding. After a 30-min
incubation at room temperature, the suspensions were filtered through
GF/B glass-fiber filter strips (Whatman, Clifton, NJ) that had been
soaked overnight in 0.2% polyethylenimine, using a 48-sample manifold
(Brandel Cell Harvester, Biomedical Research and Development,
Gaithersburg, MD). The tubes and filters were washed twice with 5 ml of
ice-cold 50 mM Tris·HCl, pH 8.0, and the radioactivity on the filter
was determined by liquid scintillation spectroscopy. The
KD and Bmax values were calculated from nonlinear regression of bound
vs. free ligand concentrations.
KD values are geometric mean values, and Bmax values are arithmetic mean values.
Protein concentrations were determined according to the method of
Bradford (1976)
with bovine serum albumin used as the standard.
| |
Results |
|---|
|
|
|---|
The alpha-2 adrenergic receptors in the ciliary body,
iris and RPE/choriocapillaris of the bovine eye were characterized by saturation binding using [3H]RX821002 as the radioligand
(Berlie et al., 1995
; Galitzky et al., 1990
;
O'Rourke et al., 1994b
). [3H]RX821002 has
similar and high affinities for all four pharmacological subtypes of
the alpha-2 adrenergic receptor (O'Rourke et
al., 1994a
, 1994b
; Renouard et al., 1994
). As shown in
figure 1, binding is saturable and of high affinity
(KD ~ 0.1 nM) in all three tissues. The nonspecific binding is relatively low (20-30% at the
KD concentrations). When the data are
transformed according to the Rosenthal procedure (Rosenthal, 1967
),
they fall on a straight line, indicating that a single class of binding
sites is being labeled. The iris had the highest receptor density
(Bmax = 200 fmol/mg of protein) of the three
tissues, about double that of the ciliary body and
RPE/choriocapillaris. The mean KD and
Bmax values for four saturation experiments are given in table 1. The Bmax values
for these three bovine eye tissues are 5- to 10-fold lower than that
found in the bovine neurosensory retina (Berlie et al.,
1995
).
|
|
The pharmacological characteristics of the alpha-2
adrenergic receptors in the ciliary body, iris and RPE/choriocapillaris of the bovine eye were assessed by competition radioligand binding studies. Representative curves of the inhibition of
[3H]RX821002 binding in membrane preparations by
rauwolscine, ARC-239 and norepinephrine are shown in figure
2. Table 2 gives the mean Ki values with pseudo-Hill slopes for
eight adrenergic antagonists and for norepinephrine. These are a subset
of the antagonists that we used previously to characterize the
alpha-2A, alpha-2B, alpha-2C and
alpha-2D adrenergic receptor subtypes in a variety of
tissues (Bylund et al., 1988
, 1992
; O'Rourke et
al., 1994a
, 1994b
). For purposes of comparison, table 2 includes
data for the neurosensory retina, which we have previously shown to
contain exclusively the alpha-2D subtype (Berlie et
al., 1995
), as well as the data for ciliary body, iris and
RPE/choriocapillaris. For none of the eight antagonists in the three
tissues were the pseudo-Hill slopes significantly <1.0, which is
consistent with the conclusion that only a single subtype of
alpha-2 adrenergic receptor is present in these bovine eye
tissues. Prazosin and ARC-239 are alpha-1-selective antagonists that also differentiate alpha-2A/D from
alpha-2B and alpha-2C subtypes. The low affinity
of prazosin (2- 3 µM) and ARC-239 (0.5 µM) indicates that the
predominate subtype is the alpha-2A/D rather than the
alpha-2B or alpha-2C (table 3).
The relatively high affinity of the receptors in the bovine eye tissues for oxymetazoline (20 nM) also eliminates the alpha-2B
subtype. Similarly, the affinity of spiroxatrine is consistent with
alpha-2A/D rather than the alpha-2B or
alpha-2C subtypes. The affinity of rauwolscine (10 nM) is
consistent with the alpha-2D rather than the
alpha-2A subtype, as would be expected for bovine tissues. Overall, the affinities of the drugs for the alpha-2
receptors in the bovine ciliary body, iris and RPE/choriocapillaris are similar to their affinities in the bovine neurosensory retina and
bovine pineal gland but clearly different from the human
alpha-2A, alpha-2B and alpha-2C
subtypes, as determined previously using the human clones transfected
into COS cells (table 3).
|
|
|
Rather than comparing affinities for two tissues or receptor subtypes
according to one drug at a time, it is often helpful to consider all
the drugs in a single comparison by correlating the negative logarithms
of Ki values
(pKi values). Figure 3
presents the correlation of the pKi
values for the four bovine eye tissues with our published data for the
alpha-2D receptor of the bovine pineal gland. The
correlation between each of the four eye tissues and the bovine pineal
is excellent (correlation coefficients, r = .97-1.00),
indicating that the pharmacological characteristics of the
alpha-2 receptors in these bovine tissues are identical. These results indicate that in the bovine ciliary body, iris and RPE/choriocapillaris as well as in the neurosensory retina (Berlie et al., 1995
), the predominate alpha-2 adrenergic
receptor subtype is alpha-2D.
|
We also used correlation analyses to compare the
pKi values in bovine eye tissues with
our published data for the human alpha-2A, alpha-2B and alpha-2C clones, as well as the rat
alpha-2D clone (table 4). For the
alpha-2B and alpha-2C subtypes of the
alpha-2 adrenergic receptor, the correlation coefficients
are poor (r = .31-.45), indicating that the
characteristics of these receptors are significantly different from the
four bovine ocular tissues used in this study. In contrast, the rat
alpha-2D pKi values are similar to the bovine eye tissues (r = .96-.97), supporting the conclusion that these ocular tissues are alpha-2D . The
correlation coefficients for the human alpha-2A and bovine
ocular tissues (.86-.89) are much higher than those found with the
human alpha-2B and alpha-2C subtypes (.31-.45)
but somewhat lower than those with the rat alpha-2D clone
(.97-1.00). This is as expected because the alpha-2A and
alpha-2D are orthologous subtypes and have similar correlation coefficients, as have been documented in previous studies
(O'Rourke et al., 1994b
).
|
| |
Discussion |
|---|
|
|
|---|
The mechanisms through which alpha-2 adrenergic agents
lower intraocular pressure are not well understood. Three presumed sites of action for these agonists are the ciliary nonpigmented epithelium (reduction of aqueous humor production), ciliary muscle (increase in uveoscleral outflow facility) and trabecular meshwork (increase in trabecular outflow). Recent evidence suggests that alpha-2 agonists may have differential effects at these
sites of action. In animal studies, although both apraclonidine and brimonidine have been found to reduce intraocular pressure in part by
reducing aqueous flow, brimonidine increases uveoscleral outflow
facility, whereas apraclonidine does not (Serle et al., 1991a
, 1991b
). Similar conclusions have recently been reached for human
eyes. Both alpha-2 agonists appear to lower intraocular pressure in part by decreasing aqueous humor production, presumably by
acting on the nonpigmented epithelium of the ciliary body. However,
brimonidine (Toris et al., 1995a
) and oxymetazoline (Wang et al., 1993
) appear to increase uveoscleral outflow,
whereas apraclonidine increases outflow through the trabecular meshwork (Toris et al., 1995b
). To understand the mechanisms of these
agents and the differences among them, an understanding of the
distribution of the subtype in various eye tissues is needed.
Several techniques have been used to localize alpha-2
adrenergic receptors in the eye. Initial radioligand binding studies indicated that the majority of the alpha adrenergic
receptors in the rabbit iris-ciliary body were of the
alpha-2 type (Mittag and Tormay, 1985
). The
alpha-2 adrenergic receptors were also demonstrated to exist
in the bovine retina (Bittiger et al., 1980
; Van Liefde
et al., 1993
). An autoradiographic study of
alpha-2 adrenergic receptor localization found that
alpha-2 adrenergic receptors were most dense in the inner
plexiform layer in rats and might be found in the inner nuclear and
ganglion cell layer (Zarbin et al., 1986
). A similar study
found that alpha-2 adrenergic receptors were localized to
ocular muscles, ciliary processes and retina in rat and rabbit eye
(Elena et al., 1989
). Autoradiographic studies in the human
eye found alpha-2 adrenergic receptors at high levels in the
iris epithelium and ciliary epithelium, as well in the ciliary muscle,
retina and retinal pigment epithelium (Matsuo and Cynader, 1992
).
More recent efforts have been directed at identifying which
alpha-2 adrenergic receptor subtypes are present in the eye.
Of the four pharmacological alpha-2 subtypes, only three
appear to be present in a given species. The alpha-2A
adrenergic receptor is present in humans, rabbits and pigs, whereas
alpha-2D subtype is present in the bovine, rat, mouse and
guinea pig. Because the alpha-2A and -2D pharmacological
subtypes are species orthologs and thus mutually exclusive in the same
species, they are sometimes referred to as the alpha-2A/D
subtype. The affinities of drugs inhibiting the binding of both the
agonist [125I]-p-iodoclonidine and the
antagonist [3H]rauwolscine are consistent with the
conclusion that the majority of the alpha-2 receptors in the
rabbit iris-ciliary body are of the alpha-2A subtype (Jin
et al., 1994
). Immunofluorescence microscopy with antibodies
to each of the three human alpha-2 subtypes indicates the
presence of not only the alpha-2A subtype but also the
alpha-2B and alpha-2C subtypes in rabbit ciliary
body (Huang et al., 1995
). In the bovine retina, radioligand
binding studies with [3H]RX821002 and
[3H]rauwolscine have demonstrated the presence of the
alpha-2A/D receptor and excluded the presence of even a
minor population of the alpha-2B and alpha-2C
subtypes (Berlie et al., 1995
). The presence of the
alpha-2D subtype in the bovine retina has been recently
confirmed by molecular techniques (Venkataraman et al., 1996
)
Our data indicate that the alpha-2A/D is the main, if not
the only, subtype present in the bovine ciliary body, iris,
RPE/choriocapillaris and retina. This conclusion is based on a
comparison of Ki values in the ocular
tissues with previous data from our laboratory. Some of these earlier
experiments were performed with glycylglycine buffer, whereas the
current data were obtained using a phosphate buffer. In a recent study,
we documented that buffer composition can affect the affinity of
antagonists as determined in radioligand binding experiments (Deupree
et al., 1996
). We demonstrate, however, that the affinity of
all antagonists is affected in a consistent fashion, and thus
correlation analysis of pKi values
remains a valid approach for identifying alpha-2 receptor
subtypes. Our conclusion that the alpha-2A/D is the major
subtype in bovine ocular tissues is consistent with radioligand binding
studies in the rabbit and pig, which also identify the
alpha-2A subtype as the main subtype (Jin et al.,
1994
; Wikberg-Matsson et al., 1996
). In the human ciliary
body, immunofluorescence labeling indicated the presence of
alpha-2B and alpha-2C subtypes but not the
alpha-2A subtype (Huang et al., 1995
). It is of
interest that the immunofluorescence identifies all three subtypes in
the rabbit ciliary body (Huang et al., 1995
), whereas the
radioligand approach finds only the alpha-2A subtype.
Because immunofluorescence is not a quantitative approach, it may be
that the other two subtypes are present in such low concentrations that
they are not detected by the radioligand binding technique or that they
are not functional proteins. The lack of immunofluorescence to the
alpha-2A in the human is of concern because this is the
major subtype detected by the radioligand technique in all three
species investigated to date: rabbit, porcine and bovine. As Huang
et al. (1995)
point out, the alpha-2A subtype may
well exist in the human but was not detected in their
immunofluorescence experiments, perhaps because the antibody used was
not sufficiently sensitive. It will be important to determine whether
this apparent discrepancy is really due to a species difference or the
immunofluorescence technique is providing misleading data. Thus, the
alpha-2 subtypes in human ocular tissues need to be
identified by the radioligand binding technique.
The alpha-2 adrenergic agonists are increasingly used as adjunctive agents with beta adrenergic blockers in stepwise glaucoma therapy. The ocular hypotensive effects of some adrenergic drugs may not always correlate with the protection of the optic nerve, possibly because of a reduction in posterior segment blood flow. However, the vasoconstrictive side effects of apraclonidine are seen mainly in the anterior segment and apparently do not affect blood flow to the optic nerve. Nevertheless, long-term studies are needed to evaluate the extent to which apraclonidine and other alpha-2 adrenergic agents preserve visual function. An understanding of the alpha-2 adrenergic receptor subtype mediating the ocular hypotensive effects of alpha-2 adrenergic receptor agonists will be important in designing new alpha-2 agents with increased specificity and reduced side effects.
| |
Footnotes |
|---|
Accepted for publication February 3, 1997.
Received for publication June 13, 1996.
Send reprint requests to: David B. Bylund, Ph.D., Department of Pharmacology, University of Nebraska Medical Center, 600 South 42nd Street, Box 986260, Omaha, NE 68198-6260.
| |
Abbreviation |
|---|
RPE, retinal pigment epithelium.
| |
References |
|---|
|
|
|---|
2-adrenergic receptors present in bovine retina?
Nature
287: 645-647, 1980[Medline].
2C-adrenergic receptor from the OK cell line.
Mol. Pharmacol.
45: 176-181, 1994[Abstract].
2-adrenoceptors: Pharmacological and molecular biological evidence converge.
Trends Pharmacol. Sci.
9: 356-361, 1988[Medline].
1- and
2-adrenergic receptors.
FASEB J.
6: 832-839, 1992[Abstract].
2-adrenergic receptors: Comparison of pharmacologically defined subtypes with subtypes identified by molecular cloning.
Mol. Pharmacol.
42: 1-5, 1992[Abstract].
2-adrenergic agonists in the medical treatment of glaucoma.
Curr. Opin. Ophthalmol.
5: 76-84, 1994.
2-adrenoceptors with a new antagonist: [3H]-RX821002, a 2-methoxy derivative of idazoxan.
Br. J. Pharmacol.
100: 862-866, 1990[Medline].
2-adrenergic receptor subtypes in the anterior segment of the human eye with selective antibodies.
Invest. Ophthalmol. Vis. Sci.
36: 2729-2739, 1995
2-adrenoceptor binding sites in rabbit ciliary body membranes.
Invest. Ophthalmol. Vis. Sci.
35: 2500-2508, 1994
2-adrenergic receptor subtypes.
Science
238: 650-656, 1987
2-adrenergic receptor subtypes and identification of a single amino acid in the mouse
2C10 homolog responsible for an interspecies variation in antagonist binding.
Mol. Pharmacol.
42: 16-27, 1992[Abstract].
2-adrenergic receptor family: Cloning and characterization of a human
2-adrenergic receptor subtype, the gene for which is located on chromosome 2.
Proc. Natl. Acad. Sci. U.S.A.
87: 5094-5098, 1990
2 adrenoceptor in rat submaxillary gland and the
2A and
2B adrenoceptor subtypes.
Br. J. Pharmacol.
98: 890-897, 1989[Medline].
)[3H]noradrenaline to bovine membrane of the retina: Evidence for the existence of
2-receptors.
Vision Res.
22: 1401-1407, 1982[Medline].
2-adrenoceptor stimulation in rabbit retina.
Brain Res.
553: 84-88, 1991[Medline].
2-adrenergic receptor subtype.
Proc. Natl. Acad. Sci. U.S.A.
85: 6301-6305, 1988
2-adrenergic agonists on uveoscleral outflow in rabbits (Abstract).
Invest. Ophthalmol. Vis. Sci.
32: 867, 1991a.
2D-adrenergic receptors in bovine pineal gland.
Mol. Pharmacol.
40: 235-241, 1991[Abstract].
2A,
2B, and
2C adrenoceptor subtypes: Radioligand binding and functional coupling to a cAMP-responsive reporter gene.
Biochem. Pharmacol.
51: 291-300, 1996[Medline].
2A Adrenoceptors and non-adrenergic idazoxan binding sites in calf brain and retina are distinct from those in human brain.
Neurochem. Int.
22: 501-509, 1993[Medline].
adrenergic receptor subtype in bovine retina and its photoreceptors.
Mol. Cell. Biochem.
159: 129-138, 1996[Medline].
2B-adrenergic receptor.
Mol. Pharmacol.
35: 681-688, 1990
2-adrenoceptor subtypes in the porcine eye: Identification of
2A-adrenoceptors in the choroid, ciliary body and iris, and
2A- and
2C-adrenoceptors in the retina.
Exp. Eye Res.
63: 57-65, 1996[Medline].
2B-adrenergic receptor.
Proc. Natl. Acad. Sci. U.S.A.
87: 3102-3106, 1990This article has been cited by other articles:
![]() |
A. E. de Salamanca, K. F. Siemasko, Y. Diebold, M. Calonge, J. Gao, M. Juarez-Campo, and M. E. Stern Expression of Muscarinic and Adrenergic Receptors in Normal Human Conjunctival Epithelium Invest. Ophthalmol. Vis. Sci., February 1, 2005; 46(2): 504 - 513. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Wikberg-Matsson and U. Simonsen Potent {alpha}2A-Adrenoceptor-Mediated Vasoconstriction by Brimonidine in Porcine Ciliary Arteries Invest. Ophthalmol. Vis. Sci., August 1, 2001; 42(9): 2049 - 2055. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. P. Naselsky, D. Ashton, R. R. Ruffolo Jr., and J. P. Hieble Rabbit alpha 2-Adrenoceptors: Both Platelets and Adipocytes Have alpha 2A-Pharmacology J. Pharmacol. Exp. Ther., July 1, 2001; 298(1): 219 - 225. [Abstract] [Full Text] |
||||
![]() |
D. B. Bylund and D. M. Chacko Characterization of {alpha}2 Adrenergic Receptor Subtypes in Human Ocular Tissue Homogenates Invest. Ophthalmol. Vis. Sci., September 1, 1999; 40(10): 2299 - 2306. [Abstract] [Full Text] [PDF] |
||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||